How to Break Out of an AGA Treatment Plateau on Monotherapy: Signs of Response Stagnation and Using Stem Cell Conditioned Media to Supplement the Hair Follicle Microenvironment — Dr. Moriwaki Organizes the Next Move2026.07.21

Some patients who have continued a single oral or topical AGA drug — finasteride or topical minoxidil — for over a year eventually reach a point where they feel “nothing more is being gained; keeping what I have is all I can do.” This AGA treatment plateau is by no means a rare phenomenon. It reflects both the biological ceiling of hair follicle response and the limits inherent in a treatment design that relies on a single mechanistic target. This article walks through, from Dr. Moriwaki’s clinical viewpoint, the mechanisms behind an AGA treatment plateau on monotherapy and how to assemble a next move that supplements the hair follicle microenvironment with stem cell conditioned media.

Key Points of This Article

・An AGA treatment plateau often stems from the narrow mechanistic target of finasteride or topical minoxidil

・Density gains on monotherapy tend to level off around 9 to 12 months; this is not failure but a physiological ceiling

・Because the drug is still being taken, the current state is being preserved — stopping carries a high risk of progression restarting

・Stem cell conditioned media acts on the hair follicle microenvironment (blood flow, anti-inflammation, growth factors) and can serve as a supplementary next move whose mechanism does not overlap with monotherapy

・Redesign at a plateau should be considered in the order: review objective indicators, check adherence, then reshape the treatment mix

What Is an AGA Treatment Plateau, Really?

Treatment Response Has a Physiological Ceiling

Finasteride and dutasteride inhibit 5-alpha reductase and lower DHT levels, while topical minoxidil dilates blood vessels and prolongs the anagen phase of the hair cycle. Each has a different mechanistic target, yet in both cases there is a biological upper limit to how much thicker a hair follicle that has already responded can become. The improvements in shaft diameter and density seen 3 to 6 months after starting monotherapy typically enter a plateau state around 9 to 12 months for most patients. That is what an AGA treatment plateau is. The drug has not suddenly lost its potency.

Do Not Confuse Plateau With “Not Working”

A common clinical misunderstanding is: “Nothing more is growing, so I can stop the drug.” In reality, in most cases the current state is being preserved precisely because oral or topical treatment continues. Discontinuation typically brings the DHT-dominant environment back within a few months to half a year, and progression restarts. An AGA treatment plateau is not failure — it is a phase in which progression is still being actively held back. That framing needs to come first.

Three Angles to Revisit at an AGA Treatment Plateau

Are Objective Indicators in Place?

Judging by subjective feel — “it does not seem to be growing” — is risky. Confirm whether fixed-point photography, microscope-based shaft diameter measurement, and trichoscopy hair counts per follicular unit are being recorded objectively at intervals of at least three months. Even at what looks like a plateau, subtle gains at the level of shaft diameter or hair count are not uncommon. Assessment of an AGA treatment plateau should be done in numbers, not by feeling.

Is Adherence (Quality of Medication Use) Being Maintained?

Missed doses, missed topical applications, or topical washed off right after shampooing — these small daily details cause substantial swings in the amount of active ingredient actually reaching the scalp. Even patients who describe themselves as “applying almost every day” often turn out to be missing 2 to 3 sessions a week. Before considering a next move, first re-examine whether the floor of the current regimen can be raised.

Rechecking Scalp Inflammation and Lifestyle Background

When the scalp environment or systemic condition underlying AGA — seborrheic dermatitis, chronic scalp inflammation, iron deficiency, sleep debt, heavy smoking or alcohol — deteriorates, the effect of any monotherapy erodes. The guidelines of the Japanese Dermatological Association organize the perspective of differential diagnosis and coexisting conditions in alopecia care, which is also useful when revisiting a plateau. Before doubting the limits of monotherapy, check whether the scalp — the soil — has become depleted.

Why Stem Cell Conditioned Media Can Serve as a Next Move

Its Mechanism Does Not Overlap With Monotherapy

Behind an AGA treatment plateau lie hair follicle microenvironment challenges that single mechanisms such as “5-alpha reductase inhibition” or “vasodilation” cannot fully address. Stem cell conditioned media contains a variety of growth factors — VEGF, IGF-1, HGF, FGF — along with anti-inflammatory cytokines and exosomes, and acts in a compound manner on dermal papilla cells, hair matrix cells, and the microcirculation around follicles. Because its mechanism does not overlap with monotherapy, it can offer a different entry point for breaking through a plateau. That is its clinical positioning.

What to Expect and What Not To

At the same time, stem cell conditioned media is not a magic that guarantees regrowth. It cannot restore hair follicles that have already been scarred or lost, and it is not grounds to discontinue oral or topical therapy. Its role is supplementary: a next move that layers on top of the base being preserved by monotherapy to further tune the hair follicle microenvironment. Individual variation is significant, and evaluation should track objective indicators in units of 3 to 6 months. For related reading, please also see the list of related columns on hair regenerative medicine.

Redesign From a Plateau May Also Mean Subtraction

In some patients, oral medication is being continued by inertia even as side-effect concerns have started to grow. An AGA treatment plateau is also an opportunity to re-sort which treatments to keep and which to reconsider. Under physician supervision, incorporating stem cell conditioned media as a separate axis while fine-tuning the dose, frequency, or formulation of oral therapy — a “redesign by subtraction” — is a legitimate option. There is no universal correct answer for how to face a plateau; the individualized solution depends on the follicle’s remaining capacity, tolerance for side effects, and lifestyle.

Frequently Asked Questions

Q. How long does AGA treatment usually take to enter a plateau?

For most patients, improvement in shaft diameter and density begins to slow around 9 to 12 months after starting monotherapy, entering what is called an AGA treatment plateau. That said, there is variability depending on progression stage, age, adherence, and scalp environment — some continue to improve for close to two years, while others enter the plateau within half a year.

Q. Once at a plateau, can I stop the medication?

Generally not recommended. The current state is likely being preserved because monotherapy is continuing; stopping typically allows the DHT-dominant environment to return within a few months to half a year, and progression resumes. Discontinuation should never be a solo decision — always consult your physician first.

Q. If I add stem cell conditioned media, will density definitely increase?

Not with any guarantee. Response varies with follicle capacity, degree of inflammation, and lifestyle background, and evaluation is done in units of 3 to 6 months. Medically it is positioned as “a supplement that tunes the hair follicle microenvironment through a mechanism different from monotherapy” — and it is not a treatment that restores scarred follicles. This is communicated honestly.

Q. When starting conditioned media, should I continue oral or topical therapy?

As a rule, yes — concurrent use is the default. If the preserved base is removed, the added effect of conditioned media becomes hard to evaluate. When reduction or discontinuation is considered because of side effects, pregnancy plans, or systemic conditions, the transition is done gradually under physician supervision.

Q. What objective indicators are used to judge a plateau?

Fixed-point photography, microscope-based shaft diameter measurement, and trichoscopy hair counts per follicular unit are compared at three-month intervals. Distinguishing among “stagnant, maintained, or slightly gaining” using numbers rather than feeling alone is the basic principle for judging an AGA treatment plateau.

──────────────

【Supervising Physician】Shin Moriwaki, MD

Member, Japan Society of Aesthetic Surgery (JSAS) / Member, American Academy of Aesthetic Medicine

ECFMG Certificate

──────────────

📍AVAN TOKYO Ginza Hair Regenerative Medicine

English / 中文 / Tiếng Việt supported

Please contact us via DM / LINE / Website / Phone.